VJHemOnc is pleased to be a Media Partner for the 2023 Tandem Meetings ❘ Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, which are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). These meetings featured the latest developments in the field of hematopoietic cell transplantation and cellular therapy.

View all videos

Tandem Meetings 2023

The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

15–19 February 2023 | Orlando, FL

VJHemOnc is pleased to be a Media Partner for the 2023 Tandem Meetings ❘ Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, which are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). These meetings featured the latest developments in the field of hematopoietic cell transplantation and cellular therapy.

View all videos

Outcomes with CD34-selected stem cell boost for poor graft function and graft failure after alloSCT

Muhammad Umair Mushtaq • 17 Feb 2023

Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma

Yago Nieto • 13 Feb 2023

The impact of checkpoint inhibitor-based salvage regimens in patients with R/R HL undergoing autoSCT

Sanjal Desai • 21 Jan 2023

Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML

Swati Naik • 20 Feb 2023

LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT

John DiPersio • 21 Feb 2023

LBA: update on Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL

Nirav Niranjan Shah • 15 Feb 2023

LBA: outcomes of children and young adults with B-ALL following tisa-cel reinfusion

Kevin McNerney • 24 Feb 2023

LBA: Phase III study of Iomab-B prior to allogeneic transplantation vs conventional care in R/R AML

Rajneesh Nath • 20 Feb 2023

Global trends in the use of stem cell transplantation for AML

Molly Tokaz • 2 Mar 2023

The benefit of autologous transplantation in the era of novel agents in multiple myeloma

Muzaffar Qazilbash • 24 Feb 2023

Survey on the evaluation and management of DLBCL following suboptimal response to CAR-T therapy

Nausheen Ahmed • 20 Feb 2023

Safety & efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL

Nirav Niranjan Shah • 15 Feb 2023

ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL

John DiPersio • 21 Feb 2023

Predictive factors for HLH toxicity in patients with B-ALL treated with tisa-cel

Kevin McNerney • 24 Feb 2023

Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy

Swetha Kambhampati • 23 Feb 2023

Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure

Amer Beitinjaneh • 22 Feb 2023